Dawson Rachael, Wignell Andrew, Cooling Paul, Barrett David, Vyas Harish, Davies Patrick
School of Medicine, University of Nottingham, Nottingham, UK.
School of Pharmacy, University of Nottingham, Nottingham, UK.
Paediatr Anaesth. 2019 Feb;29(2):186-192. doi: 10.1111/pan.13554. Epub 2019 Jan 8.
Plasma-Lyte 148® is a balanced, crystalloid intravenous (IV) fluid which is both calcium-free and isotonic. It prevents the hyperchloremic metabolic acidosis and iatrogenic hyponatremia seen with use of 0.9% sodium chloride and hypotonic solutions, respectively. However, data on compatibility with commonly used drugs are lacking.
To investigate the stability of Plasma-Lyte 148® and Plasma-Lyte 148® + 5% Glucose with eight commonly used therapeutic agents when compared with 5% glucose and 0.9% sodium chloride as diluents. We aimed to provide vital data which may facilitate the introduction of what appears to be a safer and more economic fluid.
Plasma-Lyte 148® and Plasma-Lyte 148® + 5% Glucose were mixed with morphine, midazolam, fentanyl, ketamine, clonidine, aminophylline, salbutamol, and furosemide at set concentrations. Comparisons were made to 0.9% sodium chloride and 5% glucose fluid controls. Six repeats of each IV fluid and drug admixture were analyzed through high-performance liquid chromatography at three time points: 0, 2, and 24 hours. A concentration change of <5% was defined as chemically stable. Physical stability was assessed by observation of precipitate formation or color change. pH changes were measured using a Fisherbrand Hydrus 300 pH meter.
Relative to starting concentration, all drugs except midazolam were stable to ±3%. All examined therapeutic agents were chemically stable at 2 and 24 hours relative to control solutions. No precipitate formed in any of the samples. All Plasma-Lyte 148® and Plasma-Lyte 148® + 5% Glucose drug admixtures remained in a safe, peripheral administration pH range of 5-9 and were closer to the pH of blood than standard fluid-drug admixtures.
Morphine, fentanyl, ketamine, salbutamol, aminophylline, and clonidine are stable for 24 hours when mixed with Plasma-Lyte 148® and Plasma-Lyte 148®+5% Glucose for administration at concentrations equivalent to those found at a typical Y-site with maintenance fluid. Furosemide is stable at lower concentrations than those seen at a Y-site, but midazolam displayed instability.
Plasma-Lyte 148®是一种平衡的晶体静脉输液,不含钙且为等渗溶液。它可分别预防使用0.9%氯化钠溶液和低渗溶液时出现的高氯性代谢性酸中毒和医源性低钠血症。然而,关于其与常用药物相容性的数据尚缺乏。
与作为稀释剂的5%葡萄糖溶液和0.9%氯化钠溶液相比,研究Plasma-Lyte 148®以及Plasma-Lyte 148® + 5%葡萄糖与八种常用治疗药物混合后的稳定性。我们旨在提供重要数据,以促进引入一种似乎更安全、更经济的输液。
将Plasma-Lyte 148®和Plasma-Lyte 148® + 5%葡萄糖与吗啡、咪达唑仑、芬太尼、氯胺酮、可乐定、氨茶碱、沙丁胺醇和呋塞米按设定浓度混合。与0.9%氯化钠溶液和5%葡萄糖溶液对照进行比较。每种静脉输液和药物混合物重复六次,在0、2和24小时三个时间点通过高效液相色谱法进行分析。浓度变化<5%被定义为化学稳定。通过观察沉淀形成或颜色变化评估物理稳定性。使用Fisherbrand Hydrus 300 pH计测量pH变化。
相对于起始浓度,除咪达唑仑外,所有药物的浓度变化均在±3%以内。相对于对照溶液,所有检测的治疗药物在2小时和24小时时化学稳定。所有样品中均未形成沉淀。所有Plasma-Lyte 148®和Plasma-Lyte 148® + 5%葡萄糖药物混合物的pH值保持在安全的外周给药范围内,即5 - 9,且比标准输液 - 药物混合物更接近血液pH值。
吗啡、芬太尼、氯胺酮、沙丁胺醇、氨茶碱和可乐定与Plasma-Lyte 148®以及Plasma-Lyte 148® + 5%葡萄糖混合,在与维持液典型Y型接口处相当的浓度下给药时,24小时内稳定。呋塞米在低于Y型接口处所见浓度时稳定,但咪达唑仑显示不稳定。